Guggenheim Reiterates Buy on Corbus Pharmaceuticals, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.6%

Neg 0% Neu 87.6% Pos 0%

Guggenheim analyst Paul Jeng reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $45 price target.

Comments

No comments yet. Be the first!